AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39425012 — intervention group
Group type: COMPARATOR
Intervention: Home-based cardiac rehabilitation program
Number of subjects: 46
Study 39425028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg per day and metronomic oral etoposide 50 mg per day d1-21 every 28 days
Number of subjects: 22
Study 39425032 — intervention group
Group type: EXPERIMENTAL
Intervention: TELESCOPE intervention: telehealth decision coaching and navigation session about LCS delivered by trained patient navigators, with a low-dose CT scan (LDCT) order placed for each patient wanting LCS.
Number of subjects: 420
Study 39425032 — intervention group
Group type: EXPERIMENTAL
Intervention: TELESCOPE intervention: telehealth decision coaching booster session with a navigator for patients whose initial LCS showed low-risk findings.
Number of subjects: 420
Study 39425032 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC): patients receive enhanced usual care from a clinician, with access to a Continuing Medical Education (CME) webinar about LCS and an LCS discussion guide.
Number of subjects: 420
Study 39425055 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Centric Approach (PC)
Number of subjects: 32
Study 39425055 — intervention group
Group type: COMPARATOR
Intervention: Centers of Excellence Approach (CoE)
Number of subjects: 32
Study 39425088 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT) for 90 minutes per week during inpatient rehabilitation
Number of subjects: 54
Study 39425088 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 90 minutes per week of gait training intervention during inpatient rehabilitation
Number of subjects: 54
Study 39425088 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT)
Number of subjects: 54
Study 39425088 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 39425090 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic counseling on behavioral health risk factors (HRFs)
Number of subjects: 225
Study 39425090 — intervention group
Group type: COMPARATOR
Intervention: Current tobacco smoking (HRF)
Number of subjects: 225
Study 39425090 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus (disease)
Number of subjects: 225
Study 39425096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes cohort
Number of subjects: 81
Study 39425120 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training app (5-week program)
Number of subjects: 120
Study 39425120 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) control group
Number of subjects: 120
Study 39425122 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT) - high frequency
Number of subjects: 144
Study 39425122 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT) - moderate frequency
Number of subjects: 144
Study 39425122 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT) - low frequency
Number of subjects: 144
Study 39425122 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 144
Study 39425155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Hypothermia at 28°C
Number of subjects: 13
Study 39425155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Hypothermia at 33°C
Number of subjects: 13
Study 39425155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Acidosis at pH 6.8
Number of subjects: 13
Study 39425155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Acidosis at pH 7.0
Number of subjects: 13
Study 39425155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Acidosis
Number of subjects: 13
Study 39425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted antibiotic stewardship intervention (ASI) including a decision-tool and toolbox, implemented with educational and evaluation sessions.
Number of subjects: 254
Study 39425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions focusing on the distinction between UTIs and asymptomatic bacteriuria held in intervention clusters.
Number of subjects: 254
Study 39425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory-action-research (PAR) approach with evaluation sessions in intervention clusters.
Number of subjects: 254
Study 39425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-tool and toolbox materials.
Number of subjects: 254
Study 39425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implementation of the multifaceted ASI.
Number of subjects: 254
Study 39425182 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (video-based encounters preferred over audio-only)
Number of subjects: 57
Study 39425182 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (general use)
Number of subjects: 57
Study 39425182 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (with initial in-person visit recommended)
Number of subjects: 57
Study 39425182 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (concerns about diagnostic accuracy)
Number of subjects: 57
Study 39425182 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (digital literacy and infrastructure concerns)
Number of subjects: 57
Study 39425208 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent SMART (technology-assisted intervention)
Number of subjects: 0
Study 39425219 — intervention group
Group type: EXPERIMENTAL
Intervention: Early minimally invasive endoscopic surgery
Number of subjects: 0
Study 39425219 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 0
Study 39425229 — intervention group
Group type: EXPERIMENTAL
Intervention: Team communication training implementation strategy
Number of subjects: 0
Study 39425229 — intervention group
Group type: COMPARATOR
Intervention: Current universal depression screening protocol
Number of subjects: 0
Study 39425234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1000 mg over 10 min prior to skin incision, maintenance dose 125 mg/h until skin closure or until 1000 mg administered)
Number of subjects: 0
Study 39425234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39425234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 39425245 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mL injection of autologous conditioned plasma after arthroscopic partial meniscectomy
Number of subjects: 90
Study 39425245 — intervention group
Group type: COMPARATOR
Intervention: Partial meniscectomy alone
Number of subjects: 90
Study 39425451 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 91
Study 39425451 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength
Number of subjects: 91
Study 39425451 — intervention group
Group type: EXPERIMENTAL
Intervention: Squats strength
Number of subjects: 91
Study 39425451 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-km walking test
Number of subjects: 91
Study 39425451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 91
Study 39425451 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall executive function (EF) score
Number of subjects: 91
Study 39425534 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination (NCT02249988)
Number of subjects: 154
Study 39425534 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational register trial (NCT03643172)
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: NA cessation
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: Baseline HBV-RNA levels
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: Detectable HBV-RNA levels
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: Predefined HBsAg cut-offs
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: Predefined anti-HBc cut-offs
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: Predefined HBcrAg cut-offs
Number of subjects: 154
Study 39425534 — intervention group
Group type: COMPARATOR
Intervention: Undetectable HBV-RNA combined with predefined cut-offs
Number of subjects: 154
Study 39425725 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cardiac magnetic resonance (CMR) imaging
Number of subjects: 1780
Study 39425725 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia and late gadolinium enhancement (LGE)
Number of subjects: 1780
Study 39425725 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia and LGE
Number of subjects: 1780
Study 39425725 — intervention group
Group type: COMPARATOR
Intervention: Patients without CMR-detected inducible ischemia
Number of subjects: 1780
Study 39425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 38
Study 39425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion
Number of subjects: 38
Study 39425927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) - 30 procedures, 60 min inhalation of pure oxygen at 2.5 atm, 5 days a week
Number of subjects: 14
Study 39425927 — intervention group
Group type: COMPARATOR
Intervention: Control group - 29 healthy male volunteers aged 25-69 years, no HBO therapy previously
Number of subjects: 14
Study 39425996 — intervention group
Group type: EXPERIMENTAL
Intervention: LearnGuide (AI-assisted training)
Number of subjects: 103
Study 39425996 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical training without AI assistance)
Number of subjects: 103
Study 39426188 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of Social Frailty Index
Number of subjects: 102
Study 39426385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab (10 mg/kg) plus platinum-based chemotherapy with or without bevacizumab
Number of subjects: 445
Study 39426385 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy with or without bevacizumab
Number of subjects: 445
Study 39426393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide (starting at 2 mg for ages 5-15 years or 5 mg for ages 16-17 years)
Number of subjects: 43
Study 39426393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 43
Study 39426396 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray pneumonia panel
Number of subjects: 1152
Study 39426396 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture and antimicrobial susceptibility testing
Number of subjects: 1152
Study 39426460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio intervention (2 oz/d)
Number of subjects: 36
Study 39426460 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 36
Study 39426756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango pulp purée ingestion
Number of subjects: 2
Study 39426785 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary
Number of subjects: 301
Study 39426785 — intervention group
Group type: COMPARATOR
Intervention: 200-mg vaginal progesterone daily
Number of subjects: 301
Study 39426836 — intervention group
Group type: EXPERIMENTAL
Intervention: GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, indapamide 1·25 mg)
Number of subjects: 1385
Study 39426836 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan-indapamide (20 mg telmisartan, 1·25 mg indapamide)
Number of subjects: 1385
Study 39426836 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan-amlodipine (20 mg telmisartan, 2·5 mg amlodipine)
Number of subjects: 1385
Study 39426836 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine-indapamide (2·5 mg amlodipine, 1·25 mg indapamide)
Number of subjects: 1385
Study 39426967 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibitors (XOIs)
Number of subjects: 49
Study 39426967 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 49
Study 39427018 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-LIFE A nomogram
Number of subjects: 328
Study 39427018 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-LIFE B nomogram
Number of subjects: 328
Study 39427067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor system with a two-minute, movement-based activity sequence
Number of subjects: 467
Study 39427067 — intervention group
Group type: COMPARATOR
Intervention: Control group (COVID-19 negative healthy controls)
Number of subjects: 467
Study 39427140 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D motion analysis
Number of subjects: 37
Study 39427140 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural analysis
Number of subjects: 37
Study 39427143 — intervention group
Group type: COMPARATOR
Intervention: IIP + Bonegraft (Control)
Number of subjects: 39
Study 39427143 — intervention group
Group type: EXPERIMENTAL
Intervention: IIP + CTG
Number of subjects: 39
Study 39427143 — intervention group
Group type: EXPERIMENTAL
Intervention: IIP + CHA
Number of subjects: 39
Study 39427163 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaverse Support Groups
Number of subjects: 3
Study 39427163 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Person Support Groups
Number of subjects: 3
Study 39427163 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 3
Study 39427182 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue injection (stem cell treatment)
Number of subjects: 30
Study 39427182 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (standard of care)
Number of subjects: 30
Study 39427187 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF6523 inhaled twice daily for 28 days
Number of subjects: 44
Study 39427187 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaled twice daily for 28 days
Number of subjects: 44
Study 39427215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) with liposomal delivery system (LDS)
Number of subjects: 211
Study 39427215 — intervention group
Group type: COMPARATOR
Intervention: Non-BC group
Number of subjects: 211
Study 39427229 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus Enzalutamide (TALA + ENZA)
Number of subjects: 33
Study 39427230 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (light and moderate-to-vigorous)
Number of subjects: 0
Study 39427332 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual diaphragm release along with respiratory training exercises
Number of subjects: 36
Study 39427332 — intervention group
Group type: COMPARATOR
Intervention: Respiratory training exercises only
Number of subjects: 36
Study 39427441 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO450 plus pembrolizumab (binimetinib 45 mg twice daily, pembrolizumab 200 mg every 3 weeks, encorafenib 450 mg once daily)
Number of subjects: 37
Study 39427441 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO300 plus pembrolizumab (binimetinib 45 mg twice daily, pembrolizumab 200 mg every 3 weeks, encorafenib 300 mg once daily)
Number of subjects: 37
Study 39427654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 18
Study 39427654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab alone
Number of subjects: 18
Study 39427654 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab or nivolumab alone
Number of subjects: 18
Study 39427688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber leadless pacemaker (Aveir DR)
Number of subjects: 399
Study 39427696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing lower rate limit of 60 beats/min for 3 months
Number of subjects: 60
Study 39427696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing rate of 80 beats/min for 3 months
Number of subjects: 60
Study 39427696 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 39427725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP goal of <120 mm Hg (N=66)
Number of subjects: 108
Study 39427725 — intervention group
Group type: COMPARATOR
Intervention: Less intensive SBP goal (N=42)
Number of subjects: 108
Study 39427924 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 38
Study 39428126 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nivolumab plus chemotherapy (ChIO)
Number of subjects: 24
Study 39428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health-based health literacy weight management intervention program using smart devices (smartwatches and mHealth app) for 12 weeks.
Number of subjects: 27
Study 39428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health applications and smartwatches for data collection.
Number of subjects: 27
Study 39428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis of focus group discussions.
Number of subjects: 27
Study 39428401 — intervention group
Group type: COMPARATOR
Intervention: sEMG reference values in healthy subjects during mandibular postural positions (MPP)
Number of subjects: 116
Study 39428401 — intervention group
Group type: COMPARATOR
Intervention: sEMG values during maximal voluntary clenching (MVC)
Number of subjects: 116
Study 39428401 — intervention group
Group type: COMPARATOR
Intervention: Mandibular kinematics assessment in TMDs patients
Number of subjects: 116
Study 39428401 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic efficiency of sEMG and mandibular kinematics for pain-free articular TMDs
Number of subjects: 116
Study 39428453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Eczema Impact Scale (HEIS)
Number of subjects: 258
Study 39428453 — intervention group
Group type: EXPERIMENTAL
Intervention: HEIS score
Number of subjects: 258
Study 39428453 — intervention group
Group type: EXPERIMENTAL
Intervention: HEIS Proximal Daily Activity Limitations (PDAL) score
Number of subjects: 258
Study 39428453 — intervention group
Group type: EXPERIMENTAL
Intervention: HEIS embarrassment with the appearance of hands (Emb) score
Number of subjects: 258
Study 39428464 — intervention group
Group type: EXPERIMENTAL
Intervention: ULFTENS stimulation on the mucosa of the tongue (TUD group)
Number of subjects: 80
Study 39428464 — intervention group
Group type: COMPARATOR
Intervention: ULFTENS stimulation on the tragus (Tragus group)
Number of subjects: 80
Study 39428490 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol (STP)
Number of subjects: 25
Study 39428517 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD) group
Number of subjects: 91
Study 39428517 — intervention group
Group type: COMPARATOR
Intervention: No closed suction drainage (no-CSD) group
Number of subjects: 91
Study 39428688 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and cytarabine (Ara-C) therapy every 35 days for six cycles
Number of subjects: 95
Study 39429032 — intervention group
Group type: COMPARATOR
Intervention: Switching to E-cigarettes
Number of subjects: 17973
Study 39429032 — intervention group
Group type: COMPARATOR
Intervention: Successful quitters
Number of subjects: 17973
Study 39429032 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued combustible cigarette users
Number of subjects: 17973
Study 39429032 — intervention group
Group type: COMPARATOR
Intervention: Switchers to E-cigarettes
Number of subjects: 17973
Study 39429032 — intervention group
Group type: COMPARATOR
Intervention: Entirely switching to E-cigarettes
Number of subjects: 17973
Study 39429046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic treatment
Number of subjects: 222
Study 39429436 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF fibrinogen increase after surgery
Number of subjects: 24
Study 39429509 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ) administered at baseline and after 3 weeks
Number of subjects: 58
Study 39429509 — intervention group
Group type: COMPARATOR
Intervention: 3 repeated and nonconsecutive 24-h dietary recalls (24DR) as a reference method
Number of subjects: 58
Study 39429541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 307
Study 39429541 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 307
Study 39429809 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg once daily
Number of subjects: 97
Study 39429809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 39429969 — intervention group
Group type: EXPERIMENTAL
Intervention: GammaTile (GT) brachytherapy
Number of subjects: 28
Study 39430169 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage kidney disease (ESKD) patients
Number of subjects: 15
Study 39430169 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 15
Study 39430399 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise (TE)
Number of subjects: 72
Study 39430399 — intervention group
Group type: COMPARATOR
Intervention: Myofascial Trigger Point Therapy (MPT)
Number of subjects: 72
Study 39430462 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (PCSK9 inhibitor) in addition to high-intensity statin therapy for 12 weeks
Number of subjects: 0
Study 39430462 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to high-intensity statin therapy for 12 weeks
Number of subjects: 0
Study 39430683 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel analgesics (mechanisms) evaluated in the study design.
Number of subjects: 0
Study 39430683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as part of the CPMP design).
Number of subjects: 0
Study 39430683 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical simulations conducted to optimize methodology and design.
Number of subjects: 0
Study 39430683 — intervention group
Group type: EXPERIMENTAL
Intervention: CPMP design.
Number of subjects: 0
Study 39430699 — intervention group
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress (DWM)
Number of subjects: 0
Study 39430699 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Number of subjects: 0
Study 39430795 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogel® Sterile Surgical undergloves
Number of subjects: 0
Study 39430795 — intervention group
Group type: COMPARATOR
Intervention: Sterile surgical undergloves from Brand 1
Number of subjects: 0